This is a routine insider sale related to equity vesting and likely tax withholding. The small size relative to market cap suggests no significant negative signal. Monitor for any subsequent Form 4 filings to see if the sale actually executes and whether other insiders follow suit.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 2 $6.46entry
- T+1 · 3mo ago +0.15%α −0.89% · $6.47
- T+5 · 2mo ago −5.73%α −4.77% · $6.09
- T+20 · 7w ago −12.23%α −12.08% · $5.67
- T+52 · todayOpen
- T+60 · in 10d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Charles Divita III filed a Form 144 to sell 18,327 shares of Teladoc Health, Inc. at an estimated value of $115,484. The shares were acquired via restricted stock vesting.
Key Facts
- Director Charles Divita III filed Form 144 to sell 18,327 shares of TDOC.
- Estimated aggregate sale value is $115,483.92.
- Shares were acquired on 09/01/2026 via restricted stock vesting.
- Sale is to be executed through Fidelity Brokerage Services LLC.
- Filing date is 09/02/2026; sale intended on or after that date.
- Previous similar sale on 06/11/2026 was to cover tax obligations from equity award settlement.
Financial Impact
Proceeds from sale are approximately $115,484, which is small relative to TDOC's $1.1B market cap and the insider's likely total holdings.
Risk Factors
- Continued insider selling could indicate lack of confidence, though this single filing is routine and small.
- Teladoc's business fundamentals remain challenged with a $1.1B market cap and mostly Hold analyst consensus.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-006651 |
| Document: 0001959173-26-006651-index.html | 0001959173-26-006651 |
| Document: 0001959173-26-006651.txt | 0001959173-26-006651 |
Track record
24 reports on TDOC
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +2.52% at T+1 after the Oct 28, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.60 Now $8.70 +1.22% settles Nov 17
- Nov 6, 202610d ago 144 Neutral 3/10 Entry $8.77 to $8.98 Now $8.70 −0.80% ▲ +2.39% +0.03% vs SPY
- Nov 3, 202613d ago 3 / PRESS-RELEASE Neutral 2/10 Entry $9.70 to $9.41 Now $8.70 −10.31% ▼ −2.99% +1.42% vs SPY
- Nov 3, 202614d ago PTAB Trial Neutral 3/10 Entry $8.89 to $9.70 Now $8.70 −2.14% ▲ +9.11% +7.46% vs SPY
- Oct 28, 202619d ago Press Release Bearish 6/10 No price data
- Oct 28, 202619d ago 8-K Bearish 6/10 Entry $8.73 to $8.51 Now $8.70 +0.34% ▲ +2.52% +0.75% vs SPY
- Oct 28, 202620d ago PTAB Trial Neutral 3/10 Entry $8.73 to $8.51 Now $8.70 −0.34% ▼ −2.52% −0.75% vs SPY
- Oct 8, 20265w ago SC 13G Neutral 3/10 Entry $5.54 to $5.77 Now $8.70 +57.04% ▲ +4.15% +3.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.09 to $5.89 Now $8.70 +42.86% ▼ −3.28% −2.54% vs SPY
- Sep 11, 20269w ago 144 Neutral 2/10 Entry $6.16 to $6.50 Now $8.70 +41.23% ▲ +5.52% +5.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers